Released: Monday 20th October 2025

Medannex Ltd (Edinburgh) today announced the presentation of the first clinical data from the ongoing Phase 1b
study of MDX-124, at the European Society for Medical Oncology (ESMO) Congress 2025.

Read the full story here.